Advertisement
Advertisement
NPCE
Neuropace, Inc. Common Stock
13.02
USDSponsored
+0.03
+0.23%
Oct 27, 15:59 UTC -4
Closed
Pre-Market
13.01
-0.01
-0.08%
Neuropace, Inc. Common Stock (NPCE) Earnings
NPCE Earnings Reports
Positive Surprise Ratio
NPCE beat 15 of 22 last estimates.
68%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$27.71M
/-$0.09
Implied change from Q2 26 (Revenue/ EPS)
+21.38%
/-50.00%
Implied change from Q3 25 (Revenue/ EPS)
+1.29%
/-18.18%
Neuropace, Inc. Common Stock earnings per share and revenue
On Aug 11, 2026, NPCE reported earnings of -0.18 USD per share (EPS) for Q2 26, beating the estimate of -0.21 USD, resulting in a 14.61% surprise. Revenue reached 22.83 million, compared to an expected 23.11 million, with a -1.22% difference. The market reacted with a -3.26% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 27.71 million USD, implying an decrease of -50.00% EPS, and increase of 21.38% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Integra LifeSciences Holdings
Report Date
Oct 21, 2026 For Q3 26
Estimate
$0.57
Actual
$0.59
Surprise
+3.04%
Beta Bionics, Inc. Common Stock
Report Date
Oct 27, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.52
Surprise
+2.73%
OrthoPediatrics Corp. Common Stock
Report Date
Oct 27, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.23
Surprise
-4.88%
Thermo Fisher Scientific, Inc.
Report Date
Oct 21, 2026 For Q3 26
Estimate
$6.46
Actual
$6.68
Surprise
+3.29%
Intuitive Surgical Inc.
Report Date
Oct 20, 2026 For Q3 26
Estimate
$2.69
Actual
$3.00
Surprise
+11.29%
IQVIA Holdings Inc.
Report Date
Oct 27, 2026 For Q3 26
Estimate
$3.30
Actual
$3.34
Surprise
+0.97%
FAQ
What were Neuropace, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Neuropace, Inc. Common Stock reported EPS of -$0.18, beating estimates by 14.61%, and revenue of $22.83M, -1.22% below expectations.
How did the market react to Neuropace, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -3.26%, changed from $15.05 before the earnings release to $14.56 the day after.
When is Neuropace, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Neuropace, Inc. Common Stock's next earnings report?
Based on 9
analysts, Neuropace, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $27.71M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.